06 January 2004
Is recombinant follicle-stimulating hormone more effective in IVF poor responders than human menopausal gonadotrophins?Mamdoh Eskandar, Kamal Jaroudi, Amal Jambi, Eric I. Archibong, Serdar Coskun, Adekunle A. Sobande
Med Sci Monit 2004; 10(1): PI6-9 :: ID: 11565
BACKGROUND: The objective of this study was to determine if the recombinant human follicle-stimulating hormone (rFSH) is more effective than human menopausal gonadotrophin (hMG) in IVF poor responders. MATERIAL/METHODS: A prospective comparative study over a 2-year period. The setting was the Tertiary IVF Center, King Faisal Specialist Hospital and Research Center. A total of 150 patients were selected from 277 patients with poor response in previous hMG-stimulated cycles who were willing to undergo another cycle of treatment. Seventy-five patients stimulated with rFSH were compared with 75 control subjects (matched for age, early follicular phase FSH, and body mass index) stimulated with urinary hMG. The number of follicles, number of oocytes retrieved, cycle cancellations, and pregnancy rates were the main outcome measures. RESULTS: There were no statistical differences in numbers of follicles (6.2 versus 5.7; p=0.97), oocytes recovered (4 versus 3.3; p=0.15), cycle characteristics, or pregnancy rates between hMG- and rFSH-stimulated cycles (p=0.32). CONCLUSIONS: Recombinant follicle-stimulating hormone (rFSH) has no advantage over urinary human menopausal gonadotrophin (hMG) on ovarian performance or the outcome of IVF-ET in poor responders' IVF cycles.
Keywords: Adult, Case-Control Studies, Fertilization in Vitro, Follicle Stimulating Hormone, Human - pharmacology, Menotropins - pharmacology, Ovulation Induction - methods, Prospective Studies, Recombinant Proteins - pharmacology, Adult, Case-Control Studies, Fertilization in Vitro, Follicle Stimulating Hormone, Human - pharmacology, Menotropins - pharmacology, Ovulation Induction - methods, Prospective Studies, Recombinant Proteins - pharmacology
18 October 2021 : EditorialEditorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-19 Pandemic
Med Sci Monit 2021; 27:e935123
20 October 2021 : EditorialEditorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atheros...
Med Sci Monit In Press; DOI: 10.12659/MSM.935172
11 October 2021 : Clinical ResearchClinical Features and Temporal Lung Radiographic Changes in 25 Patients Recovering from COVID-19 Pneumonia:...
Med Sci Monit In Press; DOI: 10.12659/MSM.933381
08 September 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit In Press; DOI: 10.12659/MSM.932788
21 Oct 2021 : Database AnalysisConstruction and Verification of a Hypoxia-Stemness-Based Gene Signature for Risk Stratification in Esophag...
Med Sci Monit In Press; DOI: 10.12659/MSM.934359
21 Oct 2021 : Database AnalysisMS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune ...
Med Sci Monit In Press; DOI: 10.12659/MSM.934597
21 Oct 2021 : Clinical ResearchPredicting Values of Neutrophil-to-Lymphocyte Ratio (NLR), High-Sensitivity C-Reactive Protein (hs-CRP), an...
Med Sci Monit In Press; DOI: 10.12659/MSM.934569
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700